Overview

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Status:
Withdrawn

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This research sub-study is being completed as a part of the Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis (Protocol #: NA_00028117). This substudy is being done to understand the efficacy of BIIB017 by measuring the nerve fiber thickness in the eye.

Phase:

Phase 3

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Biogen

Treatments:

Interferon beta-1a
Interferon-beta
Interferons